Innoviva, Inc. — 2012 Q1 Form 10-Q summary
Entity and period: The supplied filing is for Theravance, Inc. (the company’s name at the time), not Innoviva, Inc. It reports unaudited results for the three months ended March 31, 2012, with comparisons to Q1 2011 unless otherwise stated.
Business context
Theravance was a biopharmaceutical company developing medicines in respiratory disease, bacterial infections, and CNS/pain. Its key partnered respiratory programs included RELOVAIR, LAMA/LABA and MABA with GlaxoSmithKline (GSK); other programs included TD-1211 and TD-9855. Astellas terminated its VIBATIV collaboration on January 6, 2012, returning the product rights to Theravance.
Financial results and liquidity
| Metric | Q1 2012 | Q1 2011 or prior date |
|---|---|---|
| Revenue | $127.1 million | $6.3 million |
| Research and development expense | $33.2 million | $20.5 million |
| General and administrative expense | $7.9 million | $7.2 million |
| Operating income (loss) | $86.0 million | $(21.3) million |
| Net income (loss) | $84.6 million | $(22.7) million |
| Basic / diluted EPS | $1.01 / $0.93 | $(0.28) / $(0.28) |
| Net cash used in operating activities | $(41.3) million | $(25.9) million |
Q1 2012 revenue and earnings included $125.8 million of previously deferred Astellas collaboration revenue recognized upon termination of the agreement. This is a one-time accounting recognition, not evidence of a comparable increase in recurring sales. Reported revenue therefore rose 1,917% year over year. No gross margin is presented in the supplied filing text.
Cash, cash equivalents and marketable securities totaled $200.2 million at March 31, 2012, excluding $0.9 million of restricted cash, versus $240.9 million at December 31, 2011. Cash and cash equivalents alone were $14.3 million. Operating cash use increased, primarily reflecting cash uses in operating liabilities and the $127.1 million reduction in deferred revenue. Investing activities provided $8.4 million; financing activities provided $2.5 million.
Convertible subordinated notes totaled $172.5 million, due January 15, 2015, with a 3.0% coupon. Interest expense was $1.5 million. Stockholders’ equity was $6.1 million, compared with a net capital deficiency of $87.1 million at year-end, principally reflecting Q1 net income. The company reported an accumulated deficit of approximately $1.2 billion.
Material changes and developments
- Astellas ended the VIBATIV collaboration; Theravance recognized $125.8 million of deferred revenue and was no longer eligible for further Astellas milestone payments. Theravance was evaluating whether to commercialize VIBATIV alone or with partners.
- R&D expense increased 62%, mainly due to external development costs, including Phase 2 work on the PμMA and MARIN programs, and higher employee-related expense. Management expected R&D expense to increase in 2012 versus 2011. G&A expense rose 10%; management expected a slight increase for 2012.
- On April 2, 2012, Theravance agreed to issue GSK 10 million shares for approximately $212.9 million. The transaction was subject to stockholder and regulatory approvals and other conditions; it was not completed as of the filing.
Outlook, risks and contingencies
- Management stated that available cash, cash equivalents and marketable securities were expected to fund anticipated operating needs for at least 12 months under current plans. It warned that changed spending assumptions or failure to complete the GSK placement could require earlier financing; acceptable financing might not be available.
- GSK planned to file RELOVAIR regulatory applications in the U.S. and Europe beginning in mid-2012 for COPD, and in Europe for asthma; the U.S. asthma filing strategy remained under review. The LAMA/LABA Phase 3 program was progressing, with results expected in 2012. MABA Phase 3 progression depended on enabling studies.
- VIBATIV faced critical supply shortages and regional outages due to manufacturing and GMP issues at its single-source supplier. European regulators had recommended suspension of its marketing authorization, and qualifying an alternative manufacturer could take 12–24 months. Theravance also faced up to $10.4 million of VIBATIV ingredient, raw-material and finished-goods purchase commitments, subject in part to product release.
- Other principal risks included clinical or regulatory setbacks, safety concerns (including reported fatal pneumonia under investigation with RELOVAIR at the highest dose), reliance on partners and third-party manufacturers, competition, and the need for additional capital. Potential milestone payments to GSK could reach $220 million if specified vilanterol products are launched in multiple regions.
- The company reported effective disclosure controls as of March 31, 2012 and no material change in internal control over financial reporting during the quarter. Interim results were not necessarily indicative of full-year results.
Important facts for investors to verify
- Confirm the issuer identity: this document names Theravance, Inc.; it is not identified in the filing as Innoviva, Inc.
- Separate the $125.8 million Astellas deferred-revenue recognition from recurring revenue and assess the company’s post-termination revenue sources.
- Check whether the proposed $212.9 million GSK share placement closed and review its dilution and governance implications.
- Track VIBATIV supply remediation, regulatory status, purchase obligations and commercialization plans.
- Monitor cash burn against management’s 12-month liquidity statement, R&D spending plans and the $172.5 million note maturity in 2015.
- Review subsequent clinical and regulatory progress for RELOVAIR, LAMA/LABA, MABA and the internally developed pipeline.